Antisense therapy

Antisense & RNAi Therapeutics Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 15, 2021
Health, Pharmaceutical, Nucleic acids, Branches of biology, Biology, RNA, Therapeutic gene modulation, Molecular biology, Biotechnology, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Antisense therapy, Sanofi, RNA interference

The "Antisense & RNAi Therapeutics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antisense & RNAi Therapeutics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the Antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A, Acuitas Therapeutics, and Antisense Therapeutics Ltd.
  • The antisense & RNAi therapeutics market consists of sales of antisense & RNAi therapeutics products and related services by entities (organizations, sole traders and partnerships) that develop antisense & RNAi therapeutics to treat various diseases.
  • The antisense & RNAi therapeutics market covered in this report is segmented by technology into RNA interference; antisense RNA.

Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting

Retrieved on: 
Thursday, June 10, 2021
Branches of biology, Biology, Therapeutic gene modulation, Antisense RNA, Life sciences, Spinal muscular atrophy, Huntington's disease, Ionis Pharmaceuticals, Ionis, Antisense therapy, Familial amyloid polyneuropathy, Amyloidosis

CARLSBAD, Calif., June 10, 2021 /PRNewswire/ --Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies,today announced that multiple presentations highlighting advances in its ATTR amyloidosis programs will be featured during the 2021 Peripheral Nerve Society (PNS) Annual Meeting to be held virtually on June 12-13, and 25-27, 2021.

Key Points: 
  • CARLSBAD, Calif., June 10, 2021 /PRNewswire/ --Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies,today announced that multiple presentations highlighting advances in its ATTR amyloidosis programs will be featured during the 2021 Peripheral Nerve Society (PNS) Annual Meeting to be held virtually on June 12-13, and 25-27, 2021.
  • Ionis' participation highlights the advancements it's made in developing novel antisense therapies for ATTR and underscores Ionis' commitment to this patient community.
  • A founding member of Ionis, Dr. Bennett is responsible for continuing to advance antisense technology and expand Ionis' drug discovery platform.
  • He will discuss the therapeutic potential of antisense therapies to address an unprecedented range of neurological diseases, with a focus on TTR amyloidosis.

Worldwide Antisense Oligonucleotide Therapeutics Industry to 2030 - Market Trends and Global Forecasts

Retrieved on: 
Tuesday, April 6, 2021
Branches of biology, Therapeutic gene modulation, Biology, Life sciences, Molecular biology, RNA, Nucleic acids, Oligonucleotide, Biotechnology, Sense, Fomivirsen, Antisense therapy

DUBLIN, April 6, 2021 /PRNewswire/ -- The "Antisense Oligonucleotide Therapeutics Market by Target Indication, Type of Therapy, Type of Molecule Type of Generation and Key Geographies: Industry Trends and Global Forecasts, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 6, 2021 /PRNewswire/ -- The "Antisense Oligonucleotide Therapeutics Market by Target Indication, Type of Therapy, Type of Molecule Type of Generation and Key Geographies: Industry Trends and Global Forecasts, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • Since the approval of Vitravene (for the treatment of cytomegalovirus retinitis) in 1998, antisense oligonucleotide (ASO) therapies have evolved into a prominent class of therapeutics.
  • Several big pharma players have also demonstrated interest in antisense oligonucleotide therapeutics and are investing both time and capital in this domain.
  • Which geographies are the most active in conducting clinical trials on antisense oligonucleotide therapeutics?

Progenity and Ionis Pharmaceuticals Enter into Agreement to Evaluate Progenity’s Ingestible Oral Biotherapeutics Technology for Delivery of Antisense Therapies

Retrieved on: 
Tuesday, April 6, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Molecular biology, Therapeutic gene modulation, RNA, Applied genetics, Antisense therapy, Sense, Ionis, Glucagon-like peptide-1

Ionis novel antisense therapies are designed to target mRNA in a highly specific manner, so that the amount of disease-causing protein is dramatically decreased.

Key Points: 
  • Ionis novel antisense therapies are designed to target mRNA in a highly specific manner, so that the amount of disease-causing protein is dramatically decreased.
  • Were excited to work with Ionis, a leader in nucleic-acid-based biotherapeutics, to collectively evaluate the ODBS platform for the oral delivery of antisense therapies, said Harry Stylli, PhD, CEO, chairman of the board and co-founder of Progenity.
  • We believe the OBDS platform shows promise to transform the systemic delivery of diverse biotherapeutics via oral administration.
  • Progenity is developing an internal pipeline including PGN-OB1, an oral version of adalimumab and PGN-OB2, an oral version of a GLP-1 analog.

Global Antisense Oligonucleotide Therapeutics Market (2020 to 2030) - by Target Indication, Type of Therapy, Type of Molecule Type of Generation and Key Geographies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 30, 2021
Biotechnology, Pharmaceutical, Health, Branches of biology, Biology, Molecular biology, Life sciences, RNA, DNA, Sense, Virology, Biotechnology, Antisense therapy

In addition, it provides details on drug developer(s), including year of establishment, company size, and location of headquarters.

Key Points: 
  • In addition, it provides details on drug developer(s), including year of establishment, company size, and location of headquarters.
  • What are the key therapeutic areas for which antisense oligonucleotide therapeutics are being/have been developed?
  • Which geographies are the most active in conducting clinical trials on antisense oligonucleotide therapeutics?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference

Retrieved on: 
Wednesday, December 2, 2020
Therapeutic gene modulation, Antisense RNA, Spinal muscular atrophy, Life sciences, Biology, Huntington's disease, Ionis Pharmaceuticals, Genetics, Ionis, Antisense therapy

CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will participate in a virtualfireside chat at the BMO 2020 Growth and ESGConference at 3:00 p.m. E.T.

Key Points: 
  • CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will participate in a virtualfireside chat at the BMO 2020 Growth and ESGConference at 3:00 p.m. E.T.
  • A webcast replay will be available for a limited time at the same address.
  • Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs.
  • To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma.

Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference

Retrieved on: 
Tuesday, November 10, 2020
Antisense RNA, Branches of biology, Spinal muscular atrophy, Huntington's disease, Ionis Pharmaceuticals, Biology, Therapeutic gene modulation, Ionis, Life sciences, Sense, Antisense therapy

CARLSBAD, Calif., Nov. 10, 2020 /PRNewswire/ --Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)announced today that accomplished Ionis scientists will highlight the company's pioneering advancements in research and drug development in antisense technology during the RNA at the Bench and Bedside II Conference , to be held virtually Nov. 11-13, 2020.

Key Points: 
  • CARLSBAD, Calif., Nov. 10, 2020 /PRNewswire/ --Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)announced today that accomplished Ionis scientists will highlight the company's pioneering advancements in research and drug development in antisense technology during the RNA at the Bench and Bedside II Conference , to be held virtually Nov. 11-13, 2020.
  • The conference was inspired by Ionis founder and executive chairman of the board Stanley T. Crooke, M.D., Ph.D., who pioneered antisense technology and RNA-targeted therapeutics more than 30 years ago.
  • "As the leader in RNA-targeted therapeutics, Ionis is excited to participate in the RNA at the Bench and Bedside II Conference, which this year emphasizes clinical advances in cardiovascular and metabolic diseases.
  • Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs.

Cognition Therapeutics Appoints Brett P. Monia to its Board of Directors

Retrieved on: 
Tuesday, October 27, 2020
Life sciences, Antisense RNA, Therapeutic gene modulation, Biotechnology, Spinal muscular atrophy, Biology, Huntington's disease, Ionis Pharmaceuticals, Ionis, Antisense therapy, GlaxoSmithKline, C. Frank Bennett

Pittsburgh, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced the appointment of Brett P. Monia, Ph.D. to its board of directors.

Key Points: 
  • Pittsburgh, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced the appointment of Brett P. Monia, Ph.D. to its board of directors.
  • Dr. Monia is a founding member and the current CEO of Ionis Pharmaceuticals, a pioneer in antisense drug development.
  • Among his accomplishments at Ionis, Dr. Monia has negotiated and executed multiple high-value transactions in neurodegenerative diseases and other indications, building the companys reputation as a valued development partner.
  • Dr. Monia joined Isis Pharmaceuticals (now Ionis) at the time of its founding from SmithKline & French Laboratories, the predecessor of GlaxoSmithKline.

Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers

Retrieved on: 
Thursday, October 22, 2020
Branches of biology, Biology, RNA, Applied genetics, Biotechnology, Molecular biology, DNA, Oligonucleotide, Antisense therapy, GRB2, Sense

Prexigebersen is a liposomal formulation containing the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2 (Grb2).

Key Points: 
  • Prexigebersen is a liposomal formulation containing the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2 (Grb2).
  • The new patent, titled, Combination Therapy with Liposomal Antisense Oligonucleotides, (based on Application No.
  • 16/333,221), will provide broad protection for application of prexigebersen in the treatment of a variety of cancers in combination with front-line therapies.
  • This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws.

Aro Collaboration with Ionis Advances with Option Exercise

Retrieved on: 
Tuesday, October 6, 2020
Biotechnology, Pharmaceutical, Genetics, Health, Life sciences, Biotechnology, Articles, Ionis, Biopharmaceutical, Applied genetics, Antisense therapy

In December 2019, Aro and Ionis entered into a licensing and collaboration agreement to advance a defined number of ASO-Centyrin drug conjugates.

Key Points: 
  • In December 2019, Aro and Ionis entered into a licensing and collaboration agreement to advance a defined number of ASO-Centyrin drug conjugates.
  • Ionis is leveraging Aros CENTYRIN technology to enhance the activity of ASOs via tissue-specific delivery, resulting in more efficient inhibition of disease-causing RNAs and proteins.
  • Ionis work in RNA-targeted therapeutics is transformative and we look forward to the continued advancement of new ASO-Centyrin therapeutic candidates as part of our collaboration.
  • Aro is a biotechnology company focused on the research and development of a new generation of protein biologics called Centyrins.